Alcohol After Bariatric Surgery 2
Launched by UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · Feb 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The "Alcohol After Bariatric Surgery 2" clinical trial is studying how the body processes alcohol and how it affects mood and blood sugar levels in both men and women who have had sleeve gastrectomy, a type of weight-loss surgery. The researchers want to find out if there are differences between men and women in how they handle alcohol after this surgery and how drinking alcohol on an empty stomach compares to drinking it after a meal in terms of blood sugar control.
To participate in this study, you need to be between 21 and 64 years old and have had sleeve gastrectomy surgery 1 to 5 years ago. You should also drink at least one alcoholic drink per month but no more than seven drinks per week if you're a woman or 14 if you're a man. There is also a control group for people who have not had the surgery, and they will be matched in age, body type, and drinking habits. Participants can expect to take part in two types of alcohol tests while fasting or after eating a meal. This trial is currently recruiting participants and aims to gather important information that could help improve understanding of alcohol consumption after weight-loss surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Surgery groups:
- • Male and female, 21-64 yrs. of age
- • Drink at least 1 standard drink per month but no more than 7 per week (women or \> 14 for men)
- • Underwent SG surgery 1-5 years ago
- • Non-surgery control group
- • Male and female who did not undergo bariatric surgery
- • Age , BMI, race , and alcohol pattern of consumption equivalent to participants in the SG surgery groups
- Exclusion Criteria:
- • For all groups (surgery and non-surgery groups)
- • Smoking or having quit smoking less than 2 months ago
- • Pregnant or breastfeeding
- • Taking any medications that might affect alcohol metabolism
- • Anemia
- • Gastritis, colitis, Crohn's Disease, malabsorptive diseases, inflammatory diseases, liver disease, kidney disease, cancer less than five years ago, stroke, or severe organ dysfunction
- • Body weight \>450 pounds (because of a limit on body composition machine)
- • Alcohol use disorder
- • Regular use of drugs with addiction potential or regular misuse of substances
- • Abnormality on EKG as determined by a study physician to present a safety risk
About University Of Illinois At Urbana Champaign
The University of Illinois at Urbana-Champaign is a leading research institution dedicated to advancing knowledge and innovation in various fields, including health sciences. With a strong commitment to rigorous scientific inquiry, the university conducts clinical trials aimed at improving patient outcomes and understanding complex health challenges. Leveraging its multidisciplinary expertise and state-of-the-art facilities, the university collaborates with healthcare professionals and researchers to explore novel therapeutic interventions and enhance evidence-based practices. Through its clinical trials, the University of Illinois at Urbana-Champaign strives to contribute significantly to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Urbana, Illinois, United States
Patients applied
Trial Officials
Marta Y Pepino de Gruev, PhD
Principal Investigator
University of Illinois at Urbana-Champaign
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported